Insulin is the Safest Alternative to Metformin in Pregnancy
For pregnant women with gestational diabetes or type 2 diabetes who cannot use metformin, insulin is the preferred pharmacologic alternative and remains the only FDA-approved medication for diabetes management during pregnancy. 1, 2
Why Insulin is the Preferred Alternative
Insulin does not cross the placenta, has decades of established safety data, and is explicitly endorsed as first-line therapy by the American Diabetes Association 3. The 2025 Diabetes Care guidelines clearly state that "insulin should be used to manage type 1 diabetes in pregnancy and is preferred for the management of type 2 diabetes in pregnancy and GDM" 1.
Key Advantages of Insulin:
- No placental transfer: Unlike metformin (which crosses the placenta at 70-100% of maternal levels), insulin remains in maternal circulation 3, 1
- FDA-approved: The only medication with formal FDA approval for pregnancy use 4
- No long-term offspring concerns: Metformin exposure has been associated with increased childhood BMI, waist circumference, and obesity risk at ages 4-10 years in some cohorts 1
What About Oral Alternatives?
If you're considering oral agents because the patient refuses or cannot use insulin:
Metformin (Second Choice)
- Reduces neonatal hypoglycemia compared to insulin (OR 0.65) 5
- Results in lower birthweight (mean difference -69g) 5
- Critical concern: Crosses placenta freely, with long-term metabolic effects on offspring showing increased BMI and obesity in childhood 1
- Requires supplemental insulin in 14-46% of cases 1
Glyburide (NOT Recommended)
Glyburide should be avoided. Multiple studies demonstrate it is clearly inferior to both insulin and metformin 6, 7:
- 2.62-fold increased risk of macrosomia 6
- 2.04-fold increased risk of neonatal hypoglycemia 6
- Higher birthweight (mean difference +209g vs metformin) 6
The 2018 SMFM statement notes that glyburide crosses the placenta at approximately 70% of maternal levels, and there are no studies evaluating long-term offspring outcomes 3.
Clinical Decision Algorithm
Step 1: Attempt insulin first
- Modern options include automated insulin delivery (AID) systems that reduce nocturnal hypoglycemia risk 1
- Address patient concerns about injections directly
Step 2: If patient refuses insulin or has documented inability to use it safely:
- Consider metformin with informed consent about placental transfer and potential long-term offspring effects
- Counsel that 14-46% will require supplemental insulin anyway 1
Step 3: Avoid glyburide entirely given clear evidence of inferior outcomes 6, 7
Important Caveats
Metformin should NOT be used if:
- Fetal growth restriction is present 8
- Mother has hypertension or kidney disease (increased risk of small-for-gestational-age infants) 8
- Severe renal impairment (eGFR <30 mL/min/1.73 m²) due to lactic acidosis risk 2
Common Pitfall: Don't assume metformin is "safer" because it's oral. The placental transfer and emerging data on childhood metabolic effects require serious consideration 1. The Auckland cohort of the MiG TOFU study showed 9-year-old children exposed to metformin were heavier with higher waist-to-height ratios compared to insulin-exposed children 1.
Patient Preference Reality
While 76.6% of women prefer metformin over insulin 9, this preference must be balanced against the lack of long-term safety data. The clinical decision should prioritize offspring metabolic health over maternal convenience, particularly given that insulin has no known long-term effects on children while metformin's effects remain uncertain and potentially concerning 1.